Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Swiss Cancer Institute
Maia Biotechnology
National Cancer Institute (NCI)
University of California, Irvine
Duke University
Montefiore Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of California, San Diego
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
M.D. Anderson Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris
Hoosier Cancer Research Network
Thomas Jefferson University
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Regeneron Pharmaceuticals
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
QuantumLeap Healthcare Collaborative
The Netherlands Cancer Institute
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Duke University
Memorial Sloan Kettering Cancer Center
University of Chicago
Henry Ford Health System
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
University of Oklahoma
M.D. Anderson Cancer Center
Columbia University
Mayo Clinic
European Organisation for Research and Treatment of Cancer - EORTC
H. Lee Moffitt Cancer Center and Research Institute
Gruppo Oncologico Italiano di Ricerca Clinica
Memorial Sloan Kettering Cancer Center
Regeneron Pharmaceuticals
Emory University
Intergroupe Francophone de Cancerologie Thoracique
Intergroupe Francophone de Cancerologie Thoracique
Ohio State University Comprehensive Cancer Center
Regeneron Pharmaceuticals
UNICANCER
Duke University
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
City of Hope Medical Center
Alliance for Clinical Trials in Oncology
University of Chicago